Chemiluminiscence kit for detecting human epididymis secretory protein 4

Abstract

The invention discloses a chemiluminiscence kit for detecting human epididymis secretory protein 4. The kit comprises the human epididymis secretory protein 4, an acridinium ester labeled 69-G10-B8-G8detection antibody and a biotin labeled 9-C3-D12-B1 capture antibody, wherein the acridinium ester labeled 69-G10-B8-G8 detection antibody and the biotin labeled 9-C3-D12-B1 capture antibody are respectively obtained by secreting respective corresponding hybridoma cell strains 69-G10-B8-G8 and 9-C3-D12-B1. The two hybridoma cell strains are obtained by performing recombinant plasmid, protein expression, animal immunization and screening and finally subcloning on an artificially synthesized HE4 gene. The double-antibody sandwich compound disclosed by the invention is good in detection sensitivity and precision, wide in linear range, good in antigen reaction specificity and free of cross reaction.

Description

technical field [0001] The invention belongs to the technical field of detection of human epididymis secretory protein, in particular to a chemiluminescent kit for detecting human epididymis secretory protein 4. Background technique [0002] Human epididymis secretory protein 4 (HE4) is a new highly specific ovarian cancer marker, HE4 (also known as WFDC2), mainly composed of WAP-type 4-disulfide-bonded core (WFDC), and extracellular protease inhibitors high homology. The protein family of transcriptional mediators WFDC are protease inhibitors in leukocytes, and HE4 is also postulated to have a role in innate immunity. The protein gene encoded by this gene is located on chromosome 20q12~13.1, with a total length of about 12kb, consisting of 5 exons and 4 introns. The incidence rate of ovarian cancer ranks third among the three major gynecological malignancies. It is not easy to be found because of its inconspicuous early symptoms. With the increase of cancer time, the 5-ye...

AI Technical Summary

Problems solved by technology

[0005] In the prior art, for example, the patent CN201510240537.X provides a method for the detection of HE4 by acridinium ester chemiluminescence immunology based on gold magnetic particles. The surface of magnetic particles is coupled with HE4-coated antibody, and then the blank site on the surface of gold magnetic particles that is not bound to HE4-coated antibody is blocked, and then the antibody is labeled, combined with the analyte, washed, and finally chemiluminescent detection is performed. The HE4-coated antibody and acridinium ester HE4-labeled antibody selected for the patented technology are synthetic antibodies produced by existing biological companies. The types of HE4-coated antibodies and acridinium ester HE4-labeled antibodies have not been studied, nor have they been studied. How to use pairs for research, resulting in the detection sensitivity of this method is not optimal

Images